Evans Roberts III, MD

Embracing the future of diagnostic science, Dr. Roberts is actively involved in the burgeoning field of computational pathology. He recognizes that the next leap in precision medicine lies in the synergy between human expertise and Artificial Intelligence. Dr. Roberts contributes to this evolution by lending his diagnostic experience to the training and validation of AI models. By annotating digital datasets and supervising the learning processes of advanced algorithms, he helps ensure that machine learning tools are grounded in rigorous clinical reality. His work in training these models focuses on enhancing diagnostic sensitivity and workflow efficiency, effectively teaching AI to recognize complex morphological patterns. Dr. Roberts believes that by integrating AI as a "digital colleague," pathologists can unlock new levels of accuracy and predictive power, further personalizing patient care.

His portfolio of articles and presentations also covers rare and complex cases, such as therapy-related mixed-phenotype acute leukemia and the use of immunohistochemistry in diagnosing metastatic Merkel cell carcinoma. Dr. Roberts does not merely practice pathology; he documents it, analyzes it, and shares his findings with the global medical community. His regular presentations at national conferences, including the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), underscore his role as a thought leader who is shaping the conversation around molecular diagnostics.

Currently, Dr. Roberts serves as a Staff Pathologist at South Louisiana Medical Associates and holds multiple Medical Directorships, including roles at AccuReference Clinical Laboratory and previously at Empire City Medical Laboratory. In these executive capacities, he oversees the quality and compliance of laboratory operations, ensuring that the high standards of molecular testing are maintained across high-volume clinical settings.

His leadership extends to multidisciplinary tumor boards, where he integrates pathology findings with radiology and oncology data to formulate comprehensive care plans. It is in these settings that Dr. Roberts’ value is most visible: translating dense molecular data into actionable clinical strategies.

As medicine continues to advance, Dr. Evans Roberts III remains dedicated to the integration of comprehensive genomic profiling into routine patient care. His work exemplifies the modern pathologist—not just a diagnostician, but a crucial partner in the therapeutic journey, using the power of molecular science to rewrite the narrative of patient care.

• University of Minnesota Medical School - Doctor of Medicine (M.D.)

• Hematopathology
• AP/CP

• Association of Molecular Pathology

Nguyen, L. Zhang, L. Roberts, E. Comparison of Mutational Profiles and Clinical Outcomes in Patients with Acute Myeloid Leukemia with Mutated RUNX1 vs. Acute Myeloid Leukemia with Myelodysplasia-Related Changes with Mutated RUNX1. Accepted for publication in Journal of Lymphoma and Leukemia December 2019. Hirsh, S. Moroz, K. Lacey, M. Roberts, E. Kimbrell, H. Torellas-Ruiz, M. Goswami, M. The Role of Obesity in Cytologic Risk Factor Assessment of Suspicious Thyroid Nodules. Journal of the American Society of Cytopathology. 2013 October (2), Issue 1, Supplement, Page S19. (DOI 10.1016/j.jasc.2013.08.048 Trivedi, D. Co Collins, V. Roberts, E. Scopetta, J, Wu, T. Crawford, B. Nakanishi, Y. Perforated Gastric Metastasis of Merkel Cell Carcinoma Confirmed by the Immunohistochemistry for Merkel Cell Polyomavirus: Case report and review of the literature . American Journal of Clinical Pathology 2016 Sept (146), Issue suppl_1,1 September 2016,40. (DOI 10.1093/ajcp/aqw161.040) Englert D, Seal P, Parsons C, Arbour A, Roberts E, Lopez FA. Clinical case of the month: a 22-year-old man with AIDS presenting with shortness of breath and an oral lesion. J La State Med Soc. 2014 Sep-Oct;166(5):224-30. Epub 2014 Oct 12. Roberts, E., Oncale, M., Safah, H., Schmieg, J. Therapy-related T/myeloid mixed phenotype acute leukemia in a patient treated with chemotherapy for cutaneous dif use large B cell lymphoma. J La State Med. Soc. Jan-Feb;168(1).